CRISPR Therapeutics' Data Shows Promise, But RFK Jr. Appointee Could Be Negative: Analyst

benzinga.com/general/biotech/25/05/45263363/crispr-therapeutics-data-provides-promising-balance-rfk-jr-appointee

CRISPR Therapeutics AG (NASDAQ:CRSP) reported new topline study results on Wednesday to establish risk factors for atherosclerotic heart disease.
The company disclosed data regarding the first 10 patients across its Phase 1 first-in-human dose escalation trial, targeting ANGPTL3 in four…

This story appeared on benzinga.com, 2025-05-07 18:17:45.
The Entire Business World on a Single Page. Free to Use →